Many incurable diseases (e.g., cancer, neurodegeneration) involve biomolecules called ‘disordered proteins’. Considered ‘undruggable’ by the mainstream pharmaceutical industry, disordered proteins continuously change their three-dimensional shapes and lack long-lived sites with which drug-molecules can interact. Our mission is to make disordered proteins druggable. We will screen millions of disordered protein/drug-molecule pairs to learn the rules of drugging disordered proteins. Building on our expertise and working with academic and industrial partners, we will leverage cutting-edge biology, engineering, and AI to deliver new drugs and tools. To accomplish this in a manner for maximum societal benefit, we have established a Focused Research Organisation (FRO), a fully-independent not-for-profit entity dedicated to this goal.

Biotechnology

Health Care

Therapeutics

Bind Research

The Central London office focuses on innovative medical imaging solutions, led by experts in magnetic resonance technology.

People (1)

Jobs (0)

Other offices